Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
Status:
Completed
Trial end date:
2017-10-31
Target enrollment:
Participant gender:
Summary
The objective of this study was to determine the efficacy of INC424 as assessed by reduction
in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF,
or post-essential thrombocythemia (ET) MF. The safety and tolerability of INC424 and the
effects of INC424 on patient reported outcomes and the duration of response as assessed by
reduction in spleen volume was also assessed.